PMID- 20874769
OWN - NLM
STAT- MEDLINE
DCOM- 20110304
LR  - 20181201
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 73
IP  - 6
DP  - 2010 Dec
TI  - Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 
      diabetes.
PG  - 739-43
LID - 10.1111/j.1365-2265.2010.03878.x [doi]
AB  - OBJECTIVE: To observe the effects of hydrochloride pioglitazone on urinary 
      cytokine excretion in type 2 diabetes and to explore its possible reno-protective 
      mechanisms. DESIGN: Subjects and Methods. Ninety-eight patients with type 2 
      diabetes and a fasting blood glucose (FBG) levels between 7.0 and 13.0 mm and 
      glycated haemoglobin A1c (HbA1c) >/= 7.0% were assigned randomly to receive either 
      the pioglitazone (DP group) or a sulphonylurea (DS group). Another 49 healthy 
      individuals were chosen as normal controls (group NC). At the start of the study 
      and after 12 weeks of treatment, urinary cytokines including monocyte 
      chemoattractant protein-1 (MCP-1), transforming growth factor-beta1 (TGF-beta1) and 
      vascular endothelial growth factor were measured and were expressed as a ratio of 
      urinary creatinine excretion. Urinary albumin/creatinine ratio, FBG and HbA1c 
      were determined at the same time. RESULTS: The excretion of each urinary 
      cytokine, corrected for urinary creatinine, was significantly increased in both 
      groups of patients with diabetes, compared with normal controls, and after a 
      12-week treatment were significantly decreased by both therapies but the effect 
      of pioglitazone was statistically greater than with sulphonylureas. Urinary 
      albumin/UCr and both systolic and diastolic blood pressure were decreased 
      significantly by pioglitazone (P < 0.01 or P < 0.05) but not by sulphonylurea 
      treatment (P < 0.05), while there was no significant difference in FBG or HbA1c 
      between two groups. There was a positive correlation between the excretion of 
      cytokines and urinary albumin /UCr (all P < 0.01). CONCLUSIONS: This study 
      indicates that pioglitazone reduces urinary albumin excretion by a mechanism that 
      is at least partly independent of blood sugar control. The correlation of urinary 
      albumin excretion with improvement in urinary cytokines suggests that this 
      reno-protective effect of piogliazone in diabetes may be related to local 
      reduction in cytokine activity within the kidney.
CI  - (c) 2010 Blackwell Publishing Ltd.
FAU - Hu, Yuan-Yuan
AU  - Hu YY
AD  - Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui 
      Medical University, Hefei, Anhui Province, China.
FAU - Ye, Shan-Dong
AU  - Ye SD
FAU - Zhao, Li-Li
AU  - Zhao LL
FAU - Zheng, Mao
AU  - Zheng M
FAU - Wu, Feng-Zhen
AU  - Wu FZ
FAU - Chen, Yan
AU  - Chen Y
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Blood Glucose)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 6KY687524K (glimepiride)
RN  - AYI8EX34EU (Creatinine)
RN  - G4PX8C4HKV (Gliclazide)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adult
MH  - Albuminuria/chemically induced
MH  - Blood Glucose/drug effects
MH  - Blood Pressure/drug effects
MH  - Chemokine CCL2/urine
MH  - Creatinine/urine
MH  - Cytokines/*urine
MH  - Diabetes Mellitus, Type 2/*drug therapy/*urine
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gliclazide/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Thiazolidinediones/*therapeutic use
MH  - Transforming Growth Factor beta1/urine
MH  - Vascular Endothelial Growth Factor A/urine
EDAT- 2010/09/30 06:00
MHDA- 2011/03/05 06:00
CRDT- 2010/09/30 06:00
PHST- 2010/09/30 06:00 [entrez]
PHST- 2010/09/30 06:00 [pubmed]
PHST- 2011/03/05 06:00 [medline]
AID - 10.1111/j.1365-2265.2010.03878.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2010 Dec;73(6):739-43. doi: 
      10.1111/j.1365-2265.2010.03878.x.